Compugen Ltd. (NASDAQ:CGEN - Free Report) - Investment analysts at Leerink Partnrs upped their FY2025 EPS estimates for Compugen in a research report issued on Thursday, August 7th. Leerink Partnrs analyst D. Graybosch now forecasts that the biotechnology company will post earnings of ($0.38) per share for the year, up from their prior estimate of ($0.41). The consensus estimate for Compugen's current full-year earnings is ($0.03) per share. Leerink Partnrs also issued estimates for Compugen's FY2027 earnings at ($0.36) EPS and FY2028 earnings at ($0.35) EPS.
Compugen (NASDAQ:CGEN - Get Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The biotechnology company reported ($0.08) EPS for the quarter, missing analysts' consensus estimates of ($0.07) by ($0.01). The business had revenue of $1.26 million during the quarter, compared to analyst estimates of $3.95 million. Compugen had a negative net margin of 87.45% and a negative return on equity of 34.77%.
Separately, Wall Street Zen lowered shares of Compugen from a "hold" rating to a "sell" rating in a research note on Saturday.
Read Our Latest Research Report on CGEN
Compugen Stock Performance
NASDAQ CGEN traded down $0.03 during trading on Monday, reaching $1.47. The company's stock had a trading volume of 288,531 shares, compared to its average volume of 259,002. The firm has a market cap of $131.18 million, a price-to-earnings ratio of -6.68 and a beta of 2.61. Compugen has a twelve month low of $1.13 and a twelve month high of $2.66. The business's fifty day moving average price is $1.61 and its 200-day moving average price is $1.65.
Institutional Trading of Compugen
Several hedge funds and other institutional investors have recently made changes to their positions in the company. Silverarc Capital Management LLC boosted its holdings in shares of Compugen by 8.2% in the fourth quarter. Silverarc Capital Management LLC now owns 1,624,377 shares of the biotechnology company's stock valued at $2,485,000 after acquiring an additional 123,264 shares in the last quarter. ARK Investment Management LLC boosted its holdings in shares of Compugen by 20.6% in the second quarter. ARK Investment Management LLC now owns 1,072,776 shares of the biotechnology company's stock valued at $1,785,000 after acquiring an additional 183,107 shares in the last quarter. Northern Trust Corp boosted its holdings in shares of Compugen by 936.9% in the fourth quarter. Northern Trust Corp now owns 941,825 shares of the biotechnology company's stock valued at $1,441,000 after acquiring an additional 850,997 shares in the last quarter. Millennium Management LLC boosted its holdings in shares of Compugen by 77.5% in the fourth quarter. Millennium Management LLC now owns 359,397 shares of the biotechnology company's stock valued at $550,000 after acquiring an additional 156,959 shares in the last quarter. Finally, Squarepoint Ops LLC boosted its holdings in shares of Compugen by 74.0% in the fourth quarter. Squarepoint Ops LLC now owns 290,659 shares of the biotechnology company's stock valued at $445,000 after acquiring an additional 123,641 shares in the last quarter. Hedge funds and other institutional investors own 12.22% of the company's stock.
About Compugen
(
Get Free Report)
Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer.
Further Reading
Before you consider Compugen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Compugen wasn't on the list.
While Compugen currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access